O varian cancer is the fourth biggest cancer killer among American women. 1 It is estimated that 25,500 women will be newly diagnosed with ovarian cancer and 16,000 will die from their disease in 2004. 1 Most ovarian cancer patients present after the disease has spread within the peritoneal cavity (Stage III). Primary therapy is debulking surgery followed by chemotherapy using a platinium/taxane-based regimen. The clinical response rate is between 60-70% and for patients who relapse after the initial treatment, the prognosis is poor. 2, 3 The available salvage therapies are not curative and there is an urgent need for innovative approaches for the treatment of recurrent disease.
Viruses that replicate selectively in tumor cells hold considerable promise as novel therapeutic agents for the treatment of human malignancy. [4] [5] [6] [7] We previously showed that a replication-competent recombinant measles virus (MV-CEA) has potent antitumor activity against human ovarian SKOV3ip.1 tumor xenografts in mice. 8 MV-CEA is a derivative of the Edmonston B strain measles virus (MV-Edmtag) that has been genetically modified to express a soluble marker peptide, human carcinoembryonic antigen (CEA). Release of CEA into the circulation allows noninvasive monitoring of the profile of viral gene expression through regular analysis of plasma CEA levels. 9 This recombinant virus is currently being tested in a phase I clinical trial for intraperitoneal administration into patients with recurrent ovarian cancer. The oncolytic activity of MV-Edmtag is due to H/F induced cell fusion (Fig 1) . Infection of cells results in expression of the measles hemaglutinin (H) and fusion (F) membrane glycoproteins on the cell surface. 10 The H attachment protein interacts with CD46 receptors on the surfaces of neighboring cells, which subsequently triggers fusion of the two cell membranes via the F protein. 10 As a result of H and F expression, the infected cell fuses with its neighbors, forming multinucleated syncytia, which are nonviable and eventually die by apoptosis. 11, 12 These H and F fusogenic proteins have also been subcloned into expression vectors 11 or adenoviruses for cancer therapy 13 and found to induce significant bystander killing that is highly desirable in cytoreductive cancer therapy. Encouraged by the promising results obtained with MV-CEA, we are keen to evaluate the oncolytic activities of other fusogenic viruses. MV-CEA was generated and rescued using the reverse genetics system based on Edmonston B measles virus (MV-Edm).
14 Recombinant measles viruses rescued from this reverse genetics system contains a genetic tag of three nucleotide changes (MVEdmtag). Edmonston B strain measles virus (family Paramyxoviridae, genus Morbillivirus) is a laboratoryadapted strain derived from a 1954 clinical isolate that has been passaged extensively in tissue culture, resulting in loss of pathogenicity. 10 MV-Edm vaccine was initially licensed in 1963 but was found to be reactogenic, causing fever and rash in measles-naı¨ve children. 10 The virus was passaged further in chick embryo fibroblasts, giving rise to the commercially available more attenuated Moraten (MV-Moraten) vaccine, which was licensed as Attenuvax in the United States in 1968. 10, 15, 16 In contrast to wildtype measles virus, which uses SLAM (signaling lymphocyte activation molecule, CD150) expressed on activated T cells, B cells and monocytes for infection, 17 both of the laboratory-adapted Edmonston B and Moraten strains of measles viruses have acquired the ability to use CD46 as a receptor to mediate virus entry and formation of intercellular fusion. 18, 19 CD46 is ubiquitously expressed on all nucleated human cells but is often overexpressed on tumor cells, including ovarian cancer cells. 8, 20 Another member of the Paramyxovirus family, mumps virus (genus Rubulavirus), also induces cytopathic effects of intercellular fusion through its envelope glycoproteins, hemagglutinin-neuraminidase (HN) and F proteins. 21 In contrast to MV-H, the mumps HN protein uses sialic Mumps and measles vaccines for therapy of ovarian cancer R Myers et al acid-containing receptors for attachment and also has neuraminidase activity. 22 The live attenuated Jeryl-Lynn strain mumps vaccine (MuV-JL) used in this study was originally isolated from the 5-year-old daughter (JerylLynn) of Dr Maurice Hillman and subsequently attenuated by passage in embryonated hen's eggs and chick embryo fibroblasts. 22 Since 1967, more than 300 million doses of the live attenuated Jeryl-Lynn vaccine have been distributed in the United States as part of the trivalent measles, mumps, rubella vaccine (MMR) or as a monovalent form (Mumpsvax).
Typically extensive toxicology and pharmacology data are needed to support the filing to the Food and Drug Administration to use a new experimental agent as an ''Investigational New Drug (IND)'' in a clinical trial. Manufacturing of clinical grade vector suitable for human use can be a challenge. Thus, we are keen to explore the possibility of using agents that have already been approved for human use, such as the Moraten measles and/or Jeryl-Lynn mumps vaccines, as oncolytic agents for cancer therapy. Although these viruses are highly attenuated, there is a compelling rationale to test them as potential oncolytics, provided they retain their fusogenic properties. There is an extensive safety record and human experience with both of these viruses as hundreds of millions of doses of the MMR vaccine have been given safely to nonimmune children. Here, we have evaluated the antineoplastic activities of these commercially available vaccine strains of measles and mumps with the known oncolytic activity of MV-CEA in a mouse orthotopic model of human intraperitoneal ovarian cancer.
Materials and methods

Cell lines
The human epithelial ovarian cancer cell lines were maintained in alpha-MEM (Irvine Scientific, Irvine, CA) supplemented with 20% fetal bovine serum (FBS) and 2 nM glutamine (Invitrogen, Carlsbad, CA). OV202 and OV207 are low passage primary lines established at the Mayo Clinic. 23 SKOV3ip.1 was a kind gift from Dr Ellen Vitetta (University of Texas Southwestern Medical Center). African green monkey kidney Vero cells (ATCC CCL-81) used for production of MV-CEA and MuV-JL were maintained in 5% FBS-DMEM (Invitrogen).
Viruses and infection assays
Parental recombinant MV-Edmtag and MV-CEA were rescued and propagated in Vero cells as described previously.
9 MV-Moraten (Attenuvax) was produced by Merck Research Laboratories. MuV-JL was plaque purified from a monovalent vaccine (Mumpsvax) manufactured by Merck Laboratories and propagated on Vero cells. Virus titers were determined by TCID50 (50% tissue culture infective dose) titrations on Vero cells. The virus titers are calculated from TCID50 titrations 24 according to the Spearman and Ka¨rber equation and expressed as number of plaque forming units/ml of virus stock. For virus infection assays, 2 Â 10 5 cells were plated overnight in six well plates and incubated the next day with the respective viruses diluted in Opti-MEM (Invitrogen) for 2 hours at 371C. At the end of the incubation period, the virus inoculum was removed and standard media was added. At 48 hours postinfection, the cells were fixed with 0.5% glutaraldehyde, stained with 2% crystal violet and photographed. For cell killing experiments, cells were plated overnight in 96 well plates (7 Â 10 3 cells/ 50 ml per well) and infected the next day with 50 ml of virus inoculum at increasing multiplicities of infection (MOIs) of 0.001, 0.01, 0.1, 1.0, 5.0 and 10. At 6 days postinfection, cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Promega Corp., Madison, WI) according to manufacturer's instructions. Cell viability in each well is expressed as percentage of live cells compared to mockinfected controls at the respective MOIs.
In vivo experiments
All procedures involving animals were approved by and performed according to the guidelines of the Institutional Animal Care and Use Committee of Mayo Foundation. Female 5-week-old NCR athymic mice (Taconic Laboratory, Germantown, NY) were maintained in the barrier facilities of Mayo Clinic Rochester. Mice were injected intraperitoneally with 3.5 Â 10 6 SKOV3ip.1 cells resuspended in 250 ml PBS using a 25-gauge needle. After 7 days, mice were treated intraperitoneally with one or six doses (given three times per week over 2 weeks) of viruses diluted in physiologic saline to a total volume of 0.5 ml using a 28-gauge needle. There are 10 mice per treatment group (except for MV-Moraten where n ¼ 8). The control group received six doses of undiluted clarified Vero cell lysates. The four treatment groups received, respectively, one dose of MV-CEA at 1 Â 10 7 pfu; or one dose of MuV-JL at 1 Â 10 7 pfu; or six doses of MV-CEA at 1.75 Â 10 5 pfu/dose (total dose ¼ 1 Â 10 6 pfu); or six doses of MV-Moraten at 1.75 Â 10 5 pfu/dose (total dose ¼ 1 Â 10 6 pfu). Mice were euthanized when they lost more than 10% of body weight, extreme wasting, lethargy or developed ascites.
Statistical methods
The statistical significance of difference between the survival proportions of mice in the treatment groups were compared using the Log Rank Test in the Prism program. A P-value of o0.05 was considered to be significantly different.
Results
In vitro antineoplastic activities
To compare the in vitro antineoplastic activities of the fusogenic viruses, an established ovarian cancer cell line, SKOV3ip.1, and two low passage primary lines established at the Mayo Clinic, OV202 and OV207, were infected with MV-Moraten, MV-Edmtag and MuV-JL at an MOI of 0.5. Syncytium formation was evident by 48 hours postinfection but there were marked differences in the extent of fusion (Fig 1a) . To quantitate these differences, we took digital photographs of representative areas and determined the percentage area covered by syncytia using the NIH image J software (Fig 1a) . It is evident that MV-Edmtag infection spread fastest and caused the most extensive (more than 90%) cytopathic effects (cpe) in all the three cell lines. It is followed next by MuV-JL that destroyed the SKOV3ip.1 cells, and the slower MV-Moraten where at 48 hours postinfection, syncytial cpe was evident only in one of the three cell lines, OV202, but not in OV207 or SKOV3ip.1.
The cytotoxic potentials of the viruses were compared in the most sensitive cell line, SKOV3ip.1, over a 6-day period at different MOIs of 0.001, 0.01, 0.1, 1.0, 5.0 and 10.0. At all the MOIs tested, the viruses were equally potent at killing the ovarian cancer cells (Fig 1b) . Thus, it is apparent that while the fusion kinetics of both MuV-JL and MV-Moraten were variable and were slower compared to MV-Edmtag at the early time point of 48 hours (Fig 1a) , they were able to spread through the culture and induced significant cell death by 6 days postinfection (Fig 1b) .
Comparative in vivo antitumor activities
At day 0, mice were implanted intraperitoneally with 3.5 Â 10 6 SKOV3ip.1 cells and 7 days later, they were injected intraperitoneally with each of the viruses. Mice in the control group were given clarified Vero cell lysates. First, we compared the survival curves of mice treated with one dose MV-CEA (10 7 pfu) or MuV-JL (10 7 pfu) against the control group. Treatment of mice with MV-CEA or MuV-JL significantly (P ¼ 0.0005 and 0.0006, respectively) extended their survival compared to the control group (Fig 2a) .
Since the MV-Moraten virus stock provided by Merck laboratories had a titer of only 3.5 Â 10 5 pfu/ml, we were limited to a lower dosage for MV-Moraten treated mice. To achieve a total of 10 6 pfu per mouse, we increased the number of doses from one to six at 1.75 Â 10 5 pfu/dose. In order to have a valid comparison of the relative efficacies, another group of mice was also treated with six doses (1.75 Â 10 5 pfu/dose) of MV-CEA. As shown in Figure 2b , both MV-Moraten and MV-CEA at a dose of 10 6 pfu significantly enhanced the survival of mice compared to the control group (P ¼ 0.0002). Interestingly, while MV-Moraten was the slowest at inducing cpe in vitro (Fig 2a) , its antitumor efficacy was comparable to that of MV-CEA. The median survival of MV-Moratentreated mice was not statistically different from that of the MV-CEA-treated group (Table 1) .
Distribution of residual intraperitoneal tumors
Necropsy of the treated animals revealed an interesting distribution pattern of residual tumors. Mice treated with live replication-competent viruses, and whose survival was significantly prolonged, had a distinctly different tumor distribution compared to mice in the control group (Table 1 ). In the majority of these treated mice, the residual tumors were localized to the area immediately surrounding the stomach, that is, in the greater omental region at both the inner and outer curvature of the stomach, or between the stomach and spleen or between the spleen and the pancreas (Table 1) . In contrast, mice in the control group had disseminated residual tumors found throughout the peritoneal cavity (Table 1 ). Localized tumors are found only at the greater omental region while disseminated tumors are found all over the peritoneal cavity or gut. There are 10 mice per treatment group except for MV-Moraten (n ¼ 8).
Discussion
In this study, we demonstrated that two commercially available paramyxoviral vaccines, Moraten measles and Jeryl-Lynn mumps, have promising antitumor activities against human ovarian tumor xenografts established in the peritoneal cavities of immunodeficient mice. Ovarian cancer is a good candidate for intraperitoneal virotherapy as the disease remains localized in the peritoneal cavity in the majority of patients, thus allowing direct deposition of the vector into the cancer site and minimizes vector inactivation by neutralizing antibodies in the circulation. These live attenuated viruses share a common mechanism of antineoplastic activity, that is, via viral-induced fusion of the infected cell with its neighbors, leading to syncytial formation and cell death. In vivo, these live attenuated vaccines significantly prolonged the survival of tumorbearing mice and were comparable in oncolytic potencies to MV-CEA, a recombinant MV-Edmtag measles virus which is being translated for clinical testing in patients with recurrent ovarian cancer and glioma. 8, 25 We and others have demonstrated that receptor number is an important determinant of virus infectivity or vector transduction efficiency of target cells. [26] [27] [28] [29] Indeed, one of the major hindrances to effective gene delivery by type 5 adenovirus (Ad5) is poor transduction efficiency due to low expression levels of the coxsackieadenovirus receptor (CAR) on cancer cells. 29 Strategies to enhance Ad5 gene transfer include modifying and retargeting the knob proteins of the virus. [30] [31] [32] Using a panel of CHO cells expressing low to high levels of CD46 receptors, we determined that measles virus infectivity increases progressively with receptor numbers. 26 Cell fusion was minimal at low receptor levels and requires a critical level of CD46 receptors, above which cell fusion becomes extensive, creating significant cytopathic damage and cell death. 26 Interestingly, the levels of measles cellular receptor, CD46, and mumps MuV-JL receptor, sialic acid, are elevated in malignancies. 33, 34 From the perspective of cancer therapy, it would appear that measles and mumps viruses are particularly suited as potential oncolytic agents because their receptors are expressed more abundantly on tumor cells than on their normal counterparts. 33, 34 Tumor cells, in common with pathogens such as Streptococcus suis, Neisseria gonorrhoeae and Trypanosoma cruzi trypomastigotes, express high levels of CD46 or sialic acid to inhibit activation of the alternative complement pathway and thus, protect themselves from complement-mediated lysis. [33] [34] [35] [36] [37] For example, CD46, also known as membrane cofactor protein, prevents complement-mediated lysis of the cell by binding and acting as a cofactor for Factor I-mediated irreversible inactivation of C3b and C4b. 35 As such, it is widely acknowledged that high-level expression of complement regulatory proteins such as CD46, CD55 and CD59, is a major factor in limiting the efficacy of monoclonal antibody therapy, which relies on activation of complement via the antibody Fc domains. 36, 37 Clearly, an ideal anticancer agent should be tumor specific and efficient. Receptor choice determines specificity and its abundance on a cell surface determines efficiency of infection. In addition, tumor specificity can occur at the postentry intracellular level by virus exploitation of genetic defects (e.g. interferon, ras activation, p53, Rb) unique to tumor cells, which selectively allow the virus to replicate in tumor cells but not in normal cells. [38] [39] [40] [41] [42] While it has been well documented that a variety of oncolytic viruses exploit these genetic defects in tumor cells to achieve selective amplification of their genomes and viral gene expression, it is still unclear the extent to which oncolytic measles and mumps exploit these defective pathways and this question is currently under investigation.
This study also revealed that the speed of ex vivo cytopathic damage is not a good indicator of in vivo antitumor efficacy. MV-Edmtag-induced cell fusion was the fastest and appeared to be the most potent at the early time point of 2 days postinfection, causing extensive cytopathic damage in the widely used ovarian cancer line, SKOV3ip.1, and two low passage cell lines established from Mayo patients. In contrast, MV-Moraten was the slowest and no syncytia were detected in the SKOV3ip.1 cells at day 2, although all three viruses induced comparable amount of cell killing by 6 days postinfection. In vivo, the median survival times of tumor-bearing mice treated with MV-CEA, MV-Moraten or MuV-JL were comparable. The ability of the slower spreading viruses to cause comparable antineoplastic activity is likely due to their abilities to replicate in the target cells and ''catch up'' with the faster virus. However, it is also important to point out that while survival was prolonged and the mice appeared healthy, most of these mice were not cured. Residual tumors containing viruses were found during necropsy at the end of the experimental period of 3 months.
It is also interesting to note that the majority of animals treated with MV-CEA, MV-Moraten and MuV-JL had tumors localized in the area surrounding the stomach, that is, under the greater curvature of the stomach, between stomach and spleen and between spleen and pancreas. This area is where the greater omentum is found. The greater omentum is an extension of the mesothelium that becomes drawn out and folded on itself during development. Studded on the surface of the greater omental fold are numerous milky spots composed mainly of macrophages. 43, 44 It has previously been demonstrated that upon experimental implantation of tumor cells into mice, tumor cells trafficked preferentially to and resided in the greater omentum. 45, 46 Hence, it is possible that while tumors distributed in the peritoneal cavity are efficiently infected and destroyed by the viruses, tumor cells residing in the greater omentum are less accessible and thus not easily infected by the virus. Also, virally infected cells in the greater omental region would likely be cleared by immune cells such as natural killer cells and macrophages. Thus, despite efficient killing of tumor cells in the peritoneal cavity, residual tumors are still found in the greater omental region in most of these mice. By analyzing plasma CEA levels in the MV-CEA-treated group, we also obtained a profile of viral gene expression in these mice (manuscript in preparation). Typically, there was a rapid increase in plasma CEA levels (due to infection and viral replication), followed by a decrease in CEA levels, likely due to destruction of tumor cells and thus, loss of substantial substrate for virus replication as mice are not permissive to measles infection. However, in almost all of the mice, there was a rebound in plasma CEA level as a result of regrowth of residual tumor cells that were not eradicated in the initial therapy. Eventually, a state of equilibrium is established between virus replication and tumor cell proliferation, keeping disease progression in check. In contrast, mice in the no vector control group had disease both in the greater omentum and disseminated over the peritoneal cavity and gut and had poorer median survival.
In conclusion, this study demonstrated the promise of using live attenuated measles and mumps vaccines for virotherapy of cancer. Oncolytic activity of mumps virus (Urabe strain) has previously been demonstrated in more than 290 patients with different malignancies, including ovarian cancer. [47] [48] [49] The patients were treated with Urabe mumps virus at titers up to 10 8-9 pfu by various routes of injection (intratumoral, intraperitoneal or intravenous). Toxicity was minimal but clinical responses were very encouraging, including partial response or total regression in 37 out of 90 patients 47 and disappearance of ascites in 26 out of 37 patients. 50 Despite the very encouraging clinical data, it is not clear why the studies did not result in widespread testing of Urabe mumps as an oncolytic. 38 It could be due to possible safety concerns with the Urabe strain. While the highly attenuated Jeryl-Lynn strain is not associated with central nervous complications (CNS) in vaccines nor causes neuropathology in rat neurovirulence or marmoset assays, the Urabe strain causes CNS complications in up to 1% of vaccines and intraspinal virus inoculation causes marmosets to develop extensive encephalitis and meningitis. 50, 51 Another parameter to factor in for virotherapy trials is availability of large-scale pure virus preparations. Our study used 10 6-7 pfu of mumps or measles vaccines for tumor therapy in mice and these doses are 1000 times higher than the typical dose (10 3-4 pfu) used for vaccination. As such, use of Moraten or Jeryl-Lynn mumps vaccines for cancer therapy will likely require a different formulation or preparation other than pooling numerous off-the-shelf vials of Attenuvax or Mumpsvax. However, potential advantages to using either MV-Moraten or MuV-JL vaccines as a single agent or in combination for cancer therapy are the known safety record and the fact that they are already licensed commercially for human use. There is extensive human experience as both of these vaccines have been given safely to millions of children as monovalent vaccines or as part of the trivalent mumps, measles, rubella vaccination program. While these viruses are not engineered to allow noninvasive monitoring of virus performance in vivo via marker peptides 9 or imaging, 52 RT-PCR for viremia could be performed on peripheral blood lymphocytes or tumor biopsy. The potential of this type of virotherapy could be hindered by the immune system as most individuals in the western hemisphere are immunized against mumps and measles viruses. However, by choosing a cancer that allows direct intratumoral (e.g. glioma, head and neck) or intraperitoneal (e.g. ovarian cancer) injection into the tumor site, virus inactivation by neutralizing antibodies could be circumvented or minimized.
